Novartis's Afinitor successful in Phase III advanced pancreatic cancer trial
This article was originally published in Scrip
Executive Summary
Novartis's Afinitor (everolimus) improved progression-free survival in patients with advanced pancreatic neuroendocrine tumours in a Phase III study, top-line data show. Detailed results from the RADIANT-3 trial may be presented at the European Society for Medical Oncology (ESMO) annual meeting in Milan, Italy, this October.